Monogram Orthopaedics, Inc. (NASDAQ:MGRM - Free Report) - Investment analysts at Roth Capital issued their FY2024 earnings per share (EPS) estimates for Monogram Orthopaedics in a research note issued on Monday, December 9th. Roth Capital analyst J. Wittes anticipates that the company will post earnings of ($0.50) per share for the year. Roth Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Monogram Orthopaedics' current full-year earnings is ($0.48) per share. Roth Capital also issued estimates for Monogram Orthopaedics' Q4 2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.49) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($0.28) EPS and FY2028 earnings at $0.06 EPS.
Separately, Roth Mkm started coverage on shares of Monogram Orthopaedics in a research note on Monday. They set a "buy" rating and a $4.00 price target for the company.
Get Our Latest Research Report on MGRM
Monogram Orthopaedics Stock Down 1.5 %
MGRM stock traded down $0.04 during midday trading on Wednesday, reaching $2.64. The stock had a trading volume of 69,948 shares, compared to its average volume of 143,675. Monogram Orthopaedics has a twelve month low of $1.53 and a twelve month high of $4.90. The firm has a market cap of $90.58 million, a price-to-earnings ratio of -5.32 and a beta of 2.01. The business has a fifty day simple moving average of $2.26 and a two-hundred day simple moving average of $2.39.
Institutional Investors Weigh In On Monogram Orthopaedics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MGRM. Barclays PLC bought a new stake in shares of Monogram Orthopaedics in the 3rd quarter valued at about $29,000. State Street Corp bought a new stake in Monogram Orthopaedics in the third quarter valued at approximately $62,000. Finally, Geode Capital Management LLC raised its holdings in Monogram Orthopaedics by 1,267.4% in the third quarter. Geode Capital Management LLC now owns 210,144 shares of the company's stock worth $557,000 after purchasing an additional 194,776 shares during the period. Institutional investors own 0.45% of the company's stock.
Monogram Orthopaedics Company Profile
(
Get Free Report)
Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.
Featured Articles
Before you consider Monogram Orthopaedics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monogram Orthopaedics wasn't on the list.
While Monogram Orthopaedics currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
